Sanofi Stock News

Can these health care stocks climb this month?

Check out the story - Adagene, Sanofi signs collaboration and license deal worth up to $2.5bn on Business-News-Today.com posted under Pharma Industry News.

These three stocks are solid value picks in different areas of healthcare.

Sanofi with ticker code (SNY) have now 4 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 68.5 and 58 calculating the average target price we see 63.63. Given that the stocks previous close was at 50.18 this indicates there is a potential upside of 26.8%. The 50 day MA is 51.58 while the 200 day moving average is 50.94. The market capitalisation for the company is $121,066m. You can visit the company''s website by visiting: https://www.sanofi.com [stock_market_widget type="chart" template="basic" color="green" assets=SNY" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $153,516m based on the market concensus. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

AstraZeneca Plc (NASDAQ: AZN ) and Sanofi SA (NASDAQ: SNY ) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory syncytial virus (RSV). The data showed that a single dose of nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% compared to placebo. The … Full story available on Benzinga.com

Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.

AstraZeneca (AZN) and Sanofi''s (SNY) single dose antibody nirsevimab met the main goal of a phase 3 trial called MELODY by reducing respiratory tract infections ((LRTI)) caused by…

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

Attorneys representing individuals living with diabetes against the pharma defendants seek certification in class-action lawsuit Attorneys at Hagens Berman representing a proposed class of insulin purchasers in a lawsuit against Sanofi, Novo Nordisk and Eli Lilly for systematic overpricing of insulin have sought to certify the lawsuit''s class, just as President Joe Biden highlighted the need to "cap the cost of insulin" in his Mar. 1, 2022 State of the Union. "We filed our motion for class certification at the exact moment President Biden addressed the nation regarding the shocking price hikes of insulin," said Steve Berman , managing partner and co-founder of Hagens Berman. "In our lawsuit against the big three makers of insulin – Sanofi, Novo Nordisk and Eli Lilly – we stand with the president and his mission of stopping the rip off, once and for all." Berman serves as court-appointed co-lead counsel representing insulin purchasers in the lawsuit. "Our clients living with diabetes have been imprisoned by this racket orchestrated by insulin makers that forces them to pay hundreds of dollars a month just to stay alive, when a vial of insulin is in fact incredibly cheap to make," Berman added. "We ask the court to approve this class of folks trapped paying the phony list price for insulin and return to them what they''ve lost over years of overpricing." The law firm filed the first-of-its-kind lawsuit in 2017 in the U.S.

Sanofi SA (NASDAQ: SNY ) has signed a collaboration with Adagene Inc (NASDAQ: ADAG ) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, … Full story available on Benzinga.com

Shares of Adagene Inc. jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%. Adagene will develop masked versions of up to four of Sanofi''s antibodies in development. Per the terms of the deal, Sanofi will pay Adadene $17.5 million now; however, the milestone payments are worth up to $2.5 billion, and the company is eligible for royalties based on sales of the therapies if they are commercialized. Adagene''s stock has tumbled 77.6% over the past year, while the S&P 500 is up 10.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endometrial Cancer Karyopharm Therapeutics, Inc. (NASDAQ: KPTI ) said following discussions with the U.S. Food and Drug Administration regarding its previously planned supplemental new drug Application for selinexor in advanced or recurrent endometrial cancer , the regulator conveyed that topline results from the Phase 3 SIENDO study are unlikely to support approval. The regulator said further exploration of patients with advanced or recurrent endometrial cancer with p53 wild-type is warranted. Taking into account, the FDA''s feedback, the company intends to initiate a new study of selinexor in patients with p53 wild-type endometrial cancer and believes top-line data will be available in the first half of 2024. The stock was slumping 26.95% to $7.59 in premarket trading. Finch Pauses Phase 3 Study Of Microbiome Therapeutic CP101 Following FDA''s Clinical Hold Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) announced that it has paused enrollment in PRISM4 Phase 3 clinical trial of CP101 in recurrent C. difficile infection following the receipt of a clinical hold letter from FDA on Feb. 24, requesting additional information about Finch''s SARS-CoV-2 donor screening protocols.

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

The ADRs of Adagene (ADAG) have climbed ~17% in the pre-market Tuesday after the China-based clinical-stage biopharmaceutical company announced a partnership with Frech pharma giant…